Avoro Capital Drops $36.3M on Scribe Therapeutics Stock — 12.4% of the Company

summarizeSummary

Avoro Capital Advisors, a director and 10% owner of Scribe Therapeutics, purchased $36.3 million in stock—12.4% of the company—in the days following the IPO, a massive vote of confidence from a key life sciences investor.

check_boxKey Events · Ownership and Investor Activity · SCTX

• Massive Post-IPO Buying Spree

  Between July 24 and July 28, Avoro Capital Advisors and affiliates purchased 2,391,238 shares for $36.3 million, representing 12.4% of Scribe Therapeutics' market cap.

• IPO Allocation and Open-Market Buys

  The buying was anchored by 2,333,333 shares acquired at the $15.00 IPO price, but an additional 57,905 shares were picked up in the open market at $22.31 and $18.25—a clear willingness to pay above the offer price.

• Ownership Concentration

  Post-transaction, Avoro holds 3,088,888 shares, including converted Series B preferred stock, making it a dominant shareholder and reducing the public float.

• Director and 10% Owner Conviction

  Behzad Aghazadeh, portfolio manager of Avoro and a Scribe board member, is the controlling person behind the purchases—aligning insider knowledge with significant capital at risk.

auto_awesomeAnalysis · SCTX · Life Sciences

In the days following Scribe Therapeutics' IPO, Avoro Capital Advisors—a director and 10% owner—deployed $36.3 million to acquire shares, a sum equal to 12.4% of the company's market cap. That level of commitment from a sophisticated life sciences investor is anything but routine. Most of the buying occurred at the $15.00 IPO price, yet Avoro also scooped up shares in the open market at $22.31 and $18.25, signaling conviction even as the stock traded above the offer price. This is a cornerstone investor doubling down immediately after the IPO, a move that dramatically shrinks the public float and telegraphs deep confidence in the company's pipeline.